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Conversion from Cyclosporine to FK 506 in Liver Allograft Recipients 
With Cyclosporine-Related Complications 
J.J. Fung,· S. Todo, A. Jain, J. McCauley, M. Alessiani, C. Scotti, and T.E. Starzl 
WITH the use of Cy A for clinical liver transplantation, I-year survival rates have approached 70%. Nev-
ertheless, allograft rejection continues to be the most 
common cause of retransplantation and death. Clinical 
rejection occurs in 70% ofliver allograft recipients on CyA 
and steroid therapy. 1 In addition, nephrotoxicity is the 
principal and dose-limiting side effect of Cy A. Chronic 
renal damage and functional impairment have been shown 
to occur in 87.4% of liver transplant patients,2 and hyper-
tension is an almost universal complication. Antihyperten-
sive therapy is required in the majority of these patients. 
Alterations in clinical immunosuppression to prevent or 
reverse these and other side effects have included (1) 
reduction of Cy A dose or (2) addition of azathioprine, 
antilymphocyte antibodies (ALG), or other agents with 
concomitant reductions in the Cy A dose. These method-
ologies have their inherent dangers: increasing susceptibil-
ity to rejection and increased susceptibility to infection, 
respectively. 
FK 506 is a potent and novel immunosuppressive agent, 
discovered in Japan less than 4 years ago.3-5 Much is 
known about FK 506: in vivo studies of the effectiveness of 
FK 506 in several allograft models in rats, dogs, and 
baboons;6-16 as well as in vitro studies of the properties of 
FK 506, its mechanisms of action, and its intrinsic cyto-
toxicity have been documented. 3-6,17,18 Both in vitro and in 
vivo synergism of FK 506 with other immunosuppressive 
drugs has been demonstrated and, for this reason, it was 
planned to give the first human patients a combination of 
FK 506 and CyA. 
A phase IIII trial of FK 506 was conducted with the 
approval of the University of Pittsburgh Institutional Re-
view Board and the FDA in 1989. The plan was to give FK 
506 to patients who were rejecting their liver grafts, in spite 
of conventional immunosuppression. 19 The protocol was 
to initially combine low doses of FK 506 with CyA. This 
was attempted in the first 11 patients. As will be described, 
this combination was accompanied by a number of adverse 
reactions. Eventually, a simple switch (clean conversion) 
was made from CyA to FK 506. The following is an 
account of the first 40 liver transplant recipients entered 
into this pilot study. 
PATIENTS AND METHODS 
Patient Profiles 
Nineteen patients were females and 21 were males, ranging from 
5 to 74 years of age. The original liver diseases and dates of liver 
transplants are noted in Table J. 
Indications 
All patients had an initial entry diagnosis of uncontrolled liver 
allograft rejection and/or other complications related to eyA, ie, 
renal dysfunction or hypertension (Table 1). eyA-related compli-
cations were defined as renal failure (a serum creatinine >2.0 
mg/dl) andlor postoperative hypertension (diastolic blood pres-
sure >100 mm Hg despite diuretics) secondary to eyA nephro-
toxicity. These patients were therefore considered treatment 
failures of conventional immunosuppression. Prior to conversion 
to FK 506, maintenance immunosuppression in all patients was 
with CyA and prednisone, with or without azathioprine. CyA 
doses had been maximized to tolerable levels, as limited by renal 
dysfunction or hypertension. 
Diagnostic Evaluations 
The cause of liver dysfunction was carefully evaluated prior to 
enrollment in the study. Ultrasonic determination of vessel pa-
tency and radiographic evaluation of the biliary system were used 
to rule out a technical or mechanical defect. Angiography was 
performed when indicated. 
Liver biopsies were performed in all but three patients prior to 
entry. An important criterion for entry was the pathologic inter-
pretation of the liver biopsy by a single experienced liver pathol-
ogist (A.J.D.), as is discussed elsewhere in this symposium. The 
histopathologic findings of rejection ranged from periportal accu-
mulations of lymphocytes without obvious duct damage to de-
struction of the bile ducts with injury to other components of the 
portal triads. 
In I patient, an incorrect initial diagnosis of acute cellular 
rejection was modified to acute hepatitis B infection, after special 
staining of the liver biopsy for hepatitis B core and surface antigen 
was positive, 4 days following initiation of FK 506 treatment. 
Treatment with FK 506 was stopped. 
In 6 patients, the clinician's opinion was that the biopsy reading 
underestimated the severity of the rejection episode. The criteria 
for rescue therapy in these patients was based primarily on 
biochemical and clinical parameters, such as elevations of serum 
transaminases or serum bilirubin to >50% of baseline, clinical 
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Table 1. FK 506 Patient Data 
Patient Date of Age Type of Date of Original Disease, Cause of Graft Graft Cause of Graft Loss or Pa-
No. Entry (yr) Sex Treatment Treatment Loss, and Indication for FK 506 Function? tient Death 
3/1/89 27 F Cryptogenic cirrhosis 
OLTX#1 7/2/85 Chronic rejection No 
OLTX#2 12128/87 Chronic rejection No 
OLTX#3 6/29/89 Acute rejection Yes 
CRT#1 3/27/89 Primary Yes 
2 3/25/89 38 M Sclerosing cholangitis 
OLTX#1 11/9/83 Primary nonfunction No 
OLTX#2 11/14/83 Chronic rejection No 
OLTX#3 12/6/85 Hepatic artery thrombosis No 
OLTX#4 2/16/86 Chronic rejection No 
OLTX#5 111/89 Acute rejection No Hepatic artery thrombosis 
OLTX#6 7/2/89 Primary Yes 
3 4/4/89 31 F Autoimmune lupoid hepatitis 
OLTX#1 6/26/84 Chronic rejection No 
OLTX#2 11/18/87 Acute rejection Yes 
Lupus nephritis 
CRT#1 8118/88 Chronic rejection No Crlronic rejection 
CRT#2 5/21/89 Primary No Mycotic aneurysm 
4 4/8189 43 F Polycystic liverlkidney disease 
OLTX#1 11/22/88 Fulminant hepatic failure No Death, liver failure 
CRT#1 11/22/88 Chronic rejection No 
5 613/89 42 M Cryptogenic cirrhosis 
OLTX#1 4/30/89 Acutelchronic rejection Yes 
6 6/30189 31 F Cryptogenic cirrhosis 
OLTX#1 1212182 Acute rejection Yes 
CRT#1 10/19/89 Primary Yes 
7 711/89 44 M Sclerosing cholangitis 
OLTX#1 6/15/86 Chronic rejection Yes 
8 7/8189 18 F ESLD secondary to toxic shock 
OLTX#1 5/13/86 Chronic rejection No 
OLTX#2 7/8/86 Acute rejection Yes 
9 7/30/89 63 F Cryptogenic cirrhosis 
OLTX#1 5/8/89 Chronic rejection No Death, operative 
10 8/2189 36 M Sclerosing cholangitis 
OLTX#1 7/10/89 Chronic rejection No Chronic rejection 
OLTX#2 8/29/89 Primary Yes 
11 8/10/89 45 F Sclerosing cholangitis 
OLTX#1 7/28/89 Acute rejection Yes 
12 9/8189 26 M Budd-Chiari 
OLTX#1 8/27/89 Acute rejection Yes 
13 9/14/89 60 M Laennec's cirrhosis 
OLTX#1 9/10/89 Acute rejection Yes 
14 9/16189 64 F Non-A-non-B hepatitis 
OLTX#1 9/14/89 Primary nonfunction No 
OLTX#2 9/16/89 Primarylrenal failure Yes 
15 9/16/89 64 M Laennec's 
OLTX#1 9/16/88 Primary nonfunction No 
OLTX#2 9/18/88 Acute rejection Yes 
16 9/20189 56 M Primary biliary cirrhosis 
OLTX#1 8/29/87 Primary Yes 
17 9/20/89 30 M Non-A-non-B hepatitis 
OLTX#1 9/16/88 Primary nonfunction No 
OLTX#2 9/25/88 Chronic rejection Yes 
18 9/21/89 61 F Non-A-non-B hepatitis 
OLTX#1 5/29/89 Chronic rejection No Chronic rejection 
OLTX#2 10/1/89 Primary Yes 
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Table 1. FK 506 Patient Data (Continued) 
Patient Date of Age Type of Date of Original Disease, Cause of Graft Graft Cause of Graft Loss or 
No. Entry (yr) Sex Treatment Treatment Loss, and Indication for FK 506 Function? Patient Death 
19 9/21/89 56 M Laennec's cirrhosis 
OLTX#l 9/6/89 Primary nonfunction No 
OLTX#2 9/8/89 Rejection, renal failure No Death, sepsis 
20 9/21/89 48 F Non-A-non-B hepatitis 
OLTX#l 4/3/87 Chronic rejection Yes 
21 9/22/89 31 M Cholangiocarcinoma 
CLUS#l 12/1/88 Renal failure Yes 
22 9/22/89 56 M Laennec's cirrhosis/hepatoma 
OLTX#1 9/9/89 Acute rejection Yes 
23 9/22/89 59 F Primary biliary cirrhosis 
OLTX#1 8/27/89 Primary nonfunction No 
OLTX#1 8/29/89 Rejection, renal failure Yes 
24 9/22/89 64 M Non-A-non-B hepatitis 
OLTX#2 9/15/89 Acute rejection Yes 
25 9/22/89 6 F Alagille's syndrome 
OLTX#l 12/9/89 Acute rejection Yes 
26 9/23/89 52 F Non-A-non-B hepatitis 
OLTX#l 9/12/89 Renal failure No Death, sepsis 
27 9/23/89 33 F Hepatitis A 
OLTX#l 9/19/89 Rejection, renal failure No Death, sepsis 
28 9/25/89 20 F Hepatitis B 
OLTX#l 6/7/89 Chronic rejection Yes 
29 9/26/89 46 F PBC/scleroderma 
OLTX#l 6/20/89 Acute rejection No 
OLTX#2 7/17/89 Renal failure Yes 
30 9/26/89 31 M Non-A-non-B hepatitis 
OLTX#1 5/5/84 Chronic rejection Yes 
31 9/27/89 44 M Non-A-non-B hepatitis 
OLTX#l 12/9/85 Acute rejection Yes 
32 9/27/89 63 M Laennec's cirrhosis 
OLTX#1 9/13/89 Chronic rejection Yes 
33 9/27/89 34 M Laennec's cirrhosis 
OLTX#l 1/22/89 Rejection, HUS Yes 
34 9/27/89 62 F Cryptogenic cirrhosis 
OLTX#l 9/23/89 Acute rejection Yes 
35 9/28/89 31 M Sclerosing cholangitis 
OLTX#l 6/21/88 Chronic rejection Yes 
36 9/28/89 64 F Primary biliary cirrhosis 
OLTX#l 3/13/89 Steroid toxicity Yes 
37 9/28/89 74 M Non-A-non-B hepatitis 
OLTX#l 5/11/89 Primary nonfunction No 
OLTX#2 5/14/89 Chronic rejection Yes 
38 9/29/89 43 F Laennec's cirrhosis 
OLTX#l 8/21/89 Acute rejection No Death, sepsis 
~_UTX#l 7/12/89 Chronic rejection No 
39 9/29/89 40 M Non-A-non-B hepatitis 
OLTX#1 12/11/87 Chronic rejection Yes 
40 9/29/89 5 F Biliary atresia 
OLTX#l 8/24/89 Acute rejection Yes 
OTLX, orthotopic liver transplant; CRT, cadaveric renal transplant; LUTX, lung transplant; ELSD, end-stage renal disease; PBC, primary biliary cirrhosis; HUS, hemolytic 
uremic syndrome. 
signs such as fever, and changes in bile characteristics in those Timing of Therapy 
that had T-tubes. In 2 patients, a large element of ischemic injury 
was noted on biopsy. Two patients had markedly abnormal Initiation of treatment with FK 506 was done in the hospital and 
coagulation parameters, making a liver biopsy unsafe. One patient was given initially as a parenteral dose, followed by conversion to 
did not have a biopsy, her entrance criterion being steroid an oral dose. Because of the possibility that FK 506 and CyA 
toxicity. would be used together, pharmacokinetic studies were performed 
CONVERSION FROM CYCLOSPORINE TO FK 506 
Table 2. Conversion Protocol for Patients on CyA to FK 506 
Dose 
First 11 patients 
FK 506 0 .15 mg/kg/d .30 mg/kg/d .30 mg/kg/d 
IV x 3 d PO x 11 d PO 
CyA* 100% 50% 30% 0% 
Next 29 patients 
FK 506 0 .15 mg/kg/d .30 mg/kg/d 
IV x 1 d PO 
CyA 100% 0% 0% 0% 
'Expressed as a percentage of baseline eyA dose. 
with each drug individually, and then in combination, with both 
intravenous and oral administration. As shown in Table 2, the 
protocol for conversion from CyA to FK 506 was different for the 
first 11 patients, after which time a "clean" conversion was 
performed for the last 29 patients. 
Size of the Dose 
The initial intravenous dose was 0.15 mg/kg/d on the first day and, 
on day 2, the daily dose was divided and given every 12 hours. On 
day 2, oral administration of 0.3 mg/kg/d began, with a I-day 
overlap between the parenteral and enteral doses. Adjustments of 
the FK 506 downward, to 0.15 mg/kg/d, was also made if side 
effects or other toxicity were encountered. 
RESULTS 
Response of the Liver Allograft 
Of the 40 patients entered in the study, I was eliminated 
from the study because of the incorrect entry diagnosis, 
which proved to be acute hepatitis B viral infection. Of the 
remaining allografts studied definitively and in which long-
term follow-up of more than I month had been obtained, 
the liver allografts were rescued, as judged by histopatho-
logic criteria and by criteria of liver function, in all but 12 
patients. In each case in which histopathologic changes 
were predominant, the findings of rejection had improved 
by the first follow-up biopsy, obtained 2 weeks following 
the start of FK 506 therapy (see Demetris et ai, this 
symposium). These changes were particularly impressive 
in patients whose pretreatment biopsies contained bile 
duct lesions that generally progressed to bile duct disap-
pearance and graft loss, in spite of intensive immunosup-
pression. 1 
The abnormalities in liver function tests were also 
promptly corrected (Figs I, 2, and 3). The decline in the 
bile cannulicular enzymes, alkaline phosphatase, and gam-
ma-guanosine triphosphate in the recipients with bile duct 
rejection was of special interest, since elevations of these 
enzymes often premonitor graft loss from chronic rejection 
(data not shown). In all of the patients who had improve-
ment in histopathologic criteria of rejection, elevations of 
hepatocellular enzymes, SGTP, and SGOT, which are 
elevated in cellular rejection, were noted to decline toward 
normal levels following FK 506 therapy. The median TBIL 
at the initiation of FK 506 conversion was 3.7 mg/dl, while 
the median value was 1.2 mg/dl 1 month and later after 
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PATIENT NUMBER 
Fig 1. Pretreatment and posttreatment values of total bilirubin in 
the 39 patients are shown. Closed circles indicate pretreatment 
values and open circles indicate posttreatment values. 
initiation of FK 506. Similar findings were noted with the 
median SGOT and SGPT levels, those being 155 IU/ml and 
287 IDlml, respectively, prior to FK 506, and 51 IUlml and 
70 IDlml, respectively, after FK 506 conversion. 
The unmistakable success of FK 506 "rescue" in a 
patient who had previously received 5 liver transplants 
over a 5-year-period and who was undergoing further 
rejection was interrupted by the thrombosis of a previously 
stenosed hepatic artery on day 100 of FK 506 therapy. 
Examination of the arterial anastomosis revealed an anas-
tomotic stricture. Microscopically, there was no evidence 
in the parenchyma of remaining cell-mediated rejection. A 
sixth liver transplant was placed, and the patient is cur-
rently successfully maintained on FK 506 (see Todo et ai, 
this symposium). 
Renal Function 
Preexisting renal dysfunction was noted in 70% of patients 
due to primary kidney disease or to CyA. Two of these 
patients had previously undergone cadaveric renal trans-
plantation in August and December of 1988. In both of 
these patients, cellular rejection and chronic fibrosis were 
seen in the kidney allograft biopsies, suggesting that both 
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Fig 2. Pretreatment and posttreatment values for SGOT (IU/ml) 
are shown for the 39 patients. Closed circles indicate pretreatment 
values and open circles indicate posttreatment values. 
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Fig 3. Pretreatment and posttreatment values for SGPT (IU/ml) 
are shown for the 39 patients. Closed circles indicate pretreatment 
values and open circles indicate posttreatment values. 
acute and chronic rejection of the kidney allografts were 
occurring. 
At the time of FK 506 conversion, 9 patients had such 
severe renal failure, including hyperkalemia, that effective 
CyA therapy was not possible. All were native kidneys, 
although 1 patient had previously undergone a native right 
nephrectomy at the time of the third liver transplantation 
and had required hemodialysis in the posttransplant pe-
riod. In 2 patients, who did not require hemodialysis, the 
creatinine and blood urea nitrogen (BUN) levels were 
markedly elevated prior to entry on FK 506. Six patients 
were already on hemodialysis at the time FK 506 therapy 
was started. 
Because of the heterogeneity of the kidneys being stud-
ied and the confounding factor or prior treatment with 
Cy A, the nephrotoxicity of FK 506 could not be accurately 
ascertained. An adverse effect of FK 506 on renal function 
in these patients appeared to be directly related to the 
interactions of FK 506 with CyA. It has been found that 
creatinine clearance is compromised in patients with Cy A, 
and that FK 506 may augment CyA nephrotoxicity (see 
McCauley et ai, this symposium). With the elimination of 
Cy A and the disappearance of detectable levels of Cy A, a 
fall in BUN and creatinine levels was usually noted. Three 
of the 6 patients on hemodialysis have actually recovered 
renal function while on FK 506 and do not require further 
hemodialysis. One patient on FK 506 required institution 
of hemodialysis after bilateral renal vein thrombosis was 
diagnosed by ultrasound, but renal function returned in 3 
weeks and the patient is currently off hemodialysis. 
In 3 patients with poor renal function at the onset of FK 
506, cadaveric renal transplantation was undertaken dur-
ing the course of FK 506 therapy for persistent renal 
failure. One patient had a serum creatinine of2.4 mg/dl and 
hyperkalemia of 6 mEq/L. She underwent transplantation 
on day 24 of FK 506 therapy, lO days after discontinuation 
of Cy A, using an en bloc set of kidneys from a 22-month-
old donor. The kidneys functioned immediately, and the 
creatinine level has been between 1.4 and 1.8 mg/dl for 
more than 7 months. In the second patient, in whom renal 
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function was markedly diminished at the onset of FK 506 
therapy, renal transplantation was performed for symp-
toms of uremia. This patient received a kidney transplant 
from a 52-year-old donor. Both kidneys from this donor 
experienced acute tubular necrosis, necessitating hemodi-
alysis following transplantation in both recipients (the 
mate recipient being transplanted under standard Cy A and 
steroids). The recipient receiving the mate kidney had 
hemorrhage from the arterial suture line during the second 
postoperative week and succumbed to a myocardial in-
farction. The cause of the hemorrhage was thought to be 
due to a mycotic aneurysm. In the patient on FK 506, 
prolonged ATN was also experienced, but renal function 
returned, liberating the patient from hemodialysis. Thirty-
one days after renal transplantation, and 79 days after FK 
506 therapy, she had a bleed from a mycotic aneurysm and 
required emergency allograft nephrectomy. The removed 
kidney had no evidence of cellular rejection and appeared 
normal. This patient is currently being maintained on 
hemodialysis. The third patient, with a baseline creatinine 
clearance of 20 mllhr, received a cadaveric kidney for 
symptoms of uremia. Her serum creatinine has been 0.7 
mg/dl on FK 506. 
Adverse Reactions 
The details of FK 506-associated side effects are discussed 
elsewhere (Shapiro et ai, this symposium). The most 
common side effect of intravenous FK 506 administration 
was headache, occurring in 70% of patients. The head-
aches responded to symptomatic treatment and did not 
require a reduction in dosage. Switching to oral adminis-
tration relieved the headache in all patients. 
The next most frequent side effects of intravenous 
therapy were nausea (65%) and vomiting (35%). Treatment 
consisted of antiemetics. Spontaneous resolution of these 
symptoms occurred in all but one patient, in whom per-
sistent symptoms were attributed to uremia. With intrave-
nous therapy, anorexia was mild and seen in all but two 
patients, generally associated with the nausea. Oral intake 
was adequate in all patients. 
No adverse hemodynamic changes, such as hypotension 
or cardiac changes, were noted during the oral or intrave-
nous administration of FK 506 (see Kang et ai, this 
symposium). In all patients who had hypertension while on 
CyA alone, antihypertensive medications were eliminated 
or reduced. 
Other side effects seen with intravenous FK 506 were a 
feeling of warmth (61%) and flushing (16%). Less frequent 
side effects were rash (10%), chest pain (without electro-
cardiographic changes) (10%), anxiety (10%), and abdom-
inal cramping, night sweats, fatigue, photophobia, and 
blurred vision (all less than 5%). These symptoms were 
also markedly reduced following oral conversion of FK 
506. A total of 74% of patients experienced no further side 
effects. 
Hyperkalemia was seen in 35% of patients following 
CONVERSION FROM CYCLOSPORINE TO FK 506 
administration of FK 506. Treatment was initiated with 
potassium-binding resins and potassium-restricted diets. 
Investigation into the cause of hyperkalemia suggested 
that the mechanism is similar to that seen in Cy A hyper-
kalemia, with adrenal suppression of mineralocorticoid 
synthesis. Addition of a synthetic mineralocorticoid, 
fludrocortisone, relieved the hyperkalemia in all of these 
patients (see McCauley et ai, this symposium). 
Mortality 
In this population of compromised patients, a total of 6 
deaths was encountered (15%). In 1 patient, who was 
removed from the study, fulminant hepatic failure from 
hepatitis B progressed. Emergency retransplantation was 
performed, but she died 2 days later from suppurative 
bacterial pneumonia. At autopsy, there was no evidence of 
vaSCUlitis, and her renal allograft did not appear to have 
any toxicity related to FK 506. 
The second patient was started on FK 506 with patho-
logic findings of late chronic rejection. These changes 
could not be reversed with FK 506. She died of technical 
causes during an attempted retransplantation. 
Four patients had systemic sepsis at the time of entry 
into the FK 506 rescue protocol. Each of these patients 
succumbed to mUltiple organ failure from sepsis. One 
patient was a 56-year-old man with a diagnosis of Laen-
nec's cirrhosis. He underwent his first liver transplant, but 
required retransplantation on the third day. His posttrans-
plant course was complicated by drainage of intraabdom-
inal abscesses and renal failure. He was started on FK 506 
on the 15th day following his initial transplant. Despite 
further drainage of abscesses, he died 15 days following 
institution of FK 506. 
The second patient was a 52-year-old woman with 
non-A-non-B chronic active hepatitis. She was febrile at 
the time of transplantation, and pancytopenic with a 
marked coagulopathy. Postoperatively, she continued to 
be febrile and remained intubated, eventually requiring a 
tracheostomy. She remained pancytopenic, with renal 
failure. She was started on FK 506 on the 12th posttrans-
plant day and, 6 days later, she died from multiorgan 
failure. At autopsy, the liver was normal, and no specific 
cause of death was identified. No vasculitis was found. 
The third septic patient was a 33-year-old woman with a 
diagnosis of fulminant hepatitis A. She was noted to have 
developed severe hemorrhagic pancreatitis at the time of 
transplantation and was taken back to the operating room 
on the fourth posttransplant day for debridement of a 
pancreatic abscess. She was oliguric throughout the post-
transplant period, requiring hemodialysis. She was placed 
on FK 506 on the fifth posttransplant day, but remained 
ventilator dependent, with thrombocytopenia requiring 
platelet transfusions until she developed a intrapulmonary 
hemorrhage and died on the 31 st postoperative day. 
The last septic patient was a 43-year-old woman with 
end-stage lung disease. She underwent double lung trans-
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plantation and was ventilator-dependent. She was found 
to have chronic end-stage liver disease after her lung 
transplantation and, 1 month later, she underwent liver 
transplantation. During the fourth week after the liver 
transplantation, she developed severe cytomegalovirus 
colitis, requiring total colectomy. She became oliguric, 
requiring hemodialysis and, on the 39th day following liver 
transplantation (10 weeks after the double lung transplan-
tation), she was started on FK 506. Her deteriorating liver 
function stabilized but she was found to have a clotted 
portal vein when a routine ultrasound was performed 
during the second week ofFK 506 therapy. She died on the 
23rd day of FK 506 therapy. 
Pharmacologic Monitoring 
Pharmacokinetic data of FK 506 are being presented 
elsewhere in this symposium (see Jain et al and Venkat et 
al). A prolongation of the half-life of CyA elimination was 
noted in patients who received both FK 506 and Cy A. In 
effect, this increased serum trough levels of Cy A and 
subsequently enhanced the toxicity of both drugs, even 
when CyA had been discontinued. 
DISCUSSION 
The phase 1111 trials began in a popUlation of patients with 
refractory complications due to Cy A, including rejection, 
hypertension, nephrotoxicity, and steroid toxicity. In this 
high-risk group of patients, many who have received 
azathioprine, OKT3, and high doses of steroids, the ben-
eficial effect of FK 506 was not expected to be a major one. 
Yet, over 70% of patients treated by conversion to FK 506 
had both clinical and histopathologic responses. Marked 
improvement in biochemical parameters was noted in a 
majority of patients. Those patients who did not respond to 
FK 506 conversion had histopathologic evidence of end-
stage chronic rejection, with obliteration of vascular lumen 
and total disappearance of intrahepatic bile duct struc-
tures. Nevertheless, a number of patients with marked 
liver function abnormalities responded by returning to 
normal levels. This phenomenon, not seen before with 
patients on CyA, OKT3, or azathioprine, may be related to 
a hepatotrophic effect of FK 506 on the liver (see Fran-
cavilla et al and Mazzaferra et ai, this symposium). While 
it is tempting to speculate on the possible role ofFK 506 on 
reparative processes following control of rejection, further 
investigations in this area are necessary. 
The nature of the high-risk patients in this study was 
exemplified by 6 deaths (4 of whom were in intensive care 
unit settings) in patients who were dependent on respira-
tory support and were also septic at the time of FK 506 
initiation. Yet, in other patients who were equally disad-
vantaged, FK 506 was able to reverse renal failure and 
maintain normal liver function. 
The several side effects seen among the first human 
subjects were related to the intravenous infusion, and 
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promptly ceased with oral conversion. Many patients also 
commented on a sense of well being, noting that they felt 
better after stopping Cy A and beginning FK 506 therapy. 
Side effects of chronic CyA administration, hirsutism, 
gingival hyperplasia, and tremors, were eliminated or 
minimized by FK 506 therapy. It is noted elsewhere in this 
symposium that FK 506 also lowered serum cholesterol 
levels, and was not associated with elevation of serum uric 
acid levels (see Van Thiel et al, this symposium). Other 
side effects reported in animals but not seen in humans are 
vasculitis, elevations in blood sugar, and cataracts. 
Other side effects are possible in humans, but only 
long-term follow-up will address this question. Side effects 
related to any potent immunosuppressive agent include 
susceptibility to opportunistic infections (see Alessiani et 
ai, this symposium), lymphoproliferative diseases, and 
other de novo malignancies. 
Finally, detailed pharmacokinetics enabled us to deter-
mine that combination immunosuppression with FK 506 
and Cy A was accompanied by elevations in serum creati-
nine and serum urea nitrogen, which fell after elimination 
of cyclosporine (see McCauley et ai, this symposium). We 
had hoped that FK 506 and CyA would be synergistic, but 
the synergism proved to be toxic reactions, making these 
agents incompatible. 
In conclusion, this study was performed to evaluate the 
efficacy, safety, and side effects of FK 506 in patients who 
had CyA-related complications, including a failure to con-
trol rejection. Patients were maintained on FK 506 for 
periods up to 7 months with minimal side effects, providing 
CyA was not continued. 
This trial has had a major effect in liver transplantation. 
The qualities of FK 506 in this clinical trial, in which FK 
506 was used as a "rescue" drug, have demonstrated 
marked clinical efficacy. Information gathered regarding 
dosage schedules, routes of elimination, and other phar-
macokinetic data have enhanced the value of this drug in 
clinical practice. Untoward side effects were carefully 
looked for, and occurred at a low frequency. 
FK 506 can be used to decrease or eliminate Cy A-
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related complications while preserving adequate immuno-
suppression. In the long run, this nlay delay or prevent the 
necessity for retransplantation, and/or greatly reduce com-
plications of CyA. FK 506 and CyA cannot be used 
together, at least with the dose schedules follov.'ed in this 
trial. 
REFERENCES 
1. Starzl TE, Demetris AJ, Van Thiel D: N Engl J Med 
391:1014,1092,1989 
2. McCauley J, Van Thiel DH, Starzl TE, et al: Nephron (in 
press) 
3. Goto T, Kino T, Hatanaka H, et al: Transplant Proc 19:4, 
1987 (suppl 6) 
4. Kino T, Hatanaka H. Hashimoto M, et al: J Antibiot 
40:124.1, 1987 
5. Kino T, Hatanaka H, Miyata S, et aI: J Antibiot 40:1256. 
1~87 
6. Ochiai T, Nakajima K, Nagata M, et al: Transplant Proc 
19: 1284. 1987 
7. Todo S, Demetris AJ, Ueda Y, et al: Transplant Proc 19:57, 
1987 (suppl 6) 
8. Todo S, Podesta L, ChapChap P, et al: Transplant Proc 
19:64, 1987 (suppl 6) 
9. Murase N, Todo S, Lee PH, et al: Transplant Proc 19:71, 
1987 (suppl 6) 
10. Ochiai T, Nagata M, Nakajima K, et al: Transplantation 
44:729, 1987 
II. Ochiai T, Nakajima K, Nagata M, et al: Transplantation 
44:734, 1987 
12. Collier DS, Thiru S, Caine R: Transplant Proc 19:62, 1987 
13. CaIne R, Collier DS, Thiru S: Transplant Proc 19:63, 1987 
14. Starzl TE, Makowka L, Todo S (eds): Transplant Proc 
19:3, 1987 (suppI6) 
15. Todo S, Ueda Y, Demetris lA, et al: Surgery 104:239, 1988 
16. Todo S, Demetris A, Ueda Y, et al: Surgery 106:444, 1989 
17. Zeevi A, Duquesnoy R, Eims G, et al: Surg Res Comm 
1:315, 1987 
18. Zeevi A, Duquesnoy R, Eiras G, et al: Transplant Proc 
19:40, 1987 
19. Starzl TE, Todo S, Fung J. et al: Lancet 2:1000,1989 
